0000000000406699

AUTHOR

Paolo D'alia

showing 2 related works from this author

Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).

2014

e20513 Background: E mesylate, a nontaxane microtubule dynamics inhibitor, was approved in the U.S in 2010 for the treatment of MBC who have previously received at least 2 MBC chemo regimens, inclu...

OncologyCancer ResearchSchedulemedicine.medical_specialtyMicrotubule dynamicsMesylatebusiness.industrybacterial infections and mycosesmedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundCombined treatmentOncologychemistryInternal medicinepolycyclic compoundsmedicinebacteriaskin and connective tissue diseasesbusinessneoplasmsmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

2014

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evalua- 15 tion to overcome treatment failure in patients experiencing recurrence. Areas covered: Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer pa…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryTreatment failureInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientTreatment FailureBiologyOvarian Neoplasmsantibody cancer vaccines cell transfer immune system immunotherapy ovarian cancer recurrence treatment strategiesPharmacologyChemotherapybusiness.industryTreatment optionsImmunotherapymedicine.diseaseClinical trialRecurrent Ovarian CancerImmunologyFemaleImmunotherapyHuman medicineNeoplasm Recurrence LocalOvarian cancerbusinessEngineering sciences. TechnologyExpert Opinion on Biological Therapy
researchProduct